Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116527 · ClinicalTrials.gov registry record · Phase 1
THC Memory & Reward Learning Pilot
A Phase 1 study of Cannabis and THC, sponsored by Hartford Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05116527: Active Phase 1 study of Cannabis and THC, sponsored by Hartford Hospital.
NCT05116527 is a Phase 1 study of Cannabis and THC that is active but no longer recruiting, run by Hartford Hospital. The registered enrollment target is 20 participants, below the 110-participant average among 24 other Cannabis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05116527, a Phase 1 study of Cannabis and THC, is active but no longer recruiting, sponsored by Hartford Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.
Interventions
- DRUG Placebo
- DRUG Marijuana, Hash, THC, or Grass
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05116527 still lists
NCT05116527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 110-participant average among 24 other Cannabis trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05116527 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05116527 about?
NCT05116527 is a clinical study titled "THC Memory & Reward Learning Pilot". Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects wi...
What is the current status of trial NCT05116527?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-07-07. Estimated completion is 2025-12.
What conditions does trial NCT05116527 study?
This clinical trial studies the following conditions: Cannabis, THC, Marijuana.
What interventions are being tested in trial NCT05116527?
The interventions under investigation include: Placebo (DRUG), Marijuana, Hash, THC, or Grass (DRUG).
Who is sponsoring clinical trial NCT05116527?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116527 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05116527's enrollment target sits among peer trials
20 22nd of 24 higher than 3 of 24 other Cannabis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
ACTIVE NOT RECRUITING · Phase 1
-
Cannabinoids, Learning, and Memory
ACTIVE NOT RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI